Subscription is FREE for qualified healthcare professionals in the US.
Subscribe or renew to PPM

All News and Research Articles

FDA will accept submissions of digital health devices to better combat opioid addiction, misuse, and treatment.
The ACP looks to support women's healthcare, and the FDA continues to improve women-centric medical devices.
An updated description of "pain" may account for the individual's intersubjective experience.
with Lawrence Robbins, MD, and representatives from Amgen/Novartis
For the treatment of insomnia, benzodiazepines should be carefully prescribed.
Amgen/Novartis have been awaiting an FDA decision on their collaborative erenumab (Aimovig), a calcitonin gene-related peptide (CGRP) monoclonal antibody for the prevention of migraine since they submitted a BLA for the novel treatment last July. Announced late in the day on May 17, 2018, FDA has granted approval to Amgen Inc.
The Task Force's inaugural public meeting will be held in late May 2018 from Washington, DC
ANI Pharmaceuticals Announces Approval of Morphine Sulfate Oral Solution for acute and chronic pain.
Focus on opioid use disorder sparks more research into the long-term effects of opioid therapy, tapering, referrals, and opioid alternatives
The company’s mission is to advance a portfolio of next-generation therapies on opioid addiction.
FDA and US administrative tone regarding opioid use for chronic pain management and treatment takes a turn; talks opened for developing evidence-based opioid prescribing guidelines.
Hunger activates a neural pathway that inhibits the perception and response to pain.
Pacira's approved expanded indication of Exparel (bupivacaine liposome injectable suspension) for upper extremity surgeries provides an extended-duration, nonopioid anesthetic alternative.